Allworth Financial’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-63
| Closed | -$13.9K | – | 5215 |
|
|
2025
Q4 | $13.9K | Buy |
63
+12
| +24% | +$1.94K | ﹤0.01% | 3033 |
|
|
2025
Q3 | $4.88K | Buy |
51
+11
| +28% | +$702 | ﹤0.01% | 3565 |
|
|
2025
Q2 | $1.95K | Hold |
40
| – | – | ﹤0.01% | 3713 |
|
|
2025
Q1 | $860 | Hold |
40
| – | – | ﹤0.01% | 3511 |
|
|
2024
Q4 | $880 | Hold |
40
| – | – | ﹤0.01% | 3439 |
|
|
2024
Q3 | $430 | Hold |
40
| – | – | ﹤0.01% | 3451 |
|
|
2024
Q2 | $473 | Hold |
40
| – | – | ﹤0.01% | 3385 |
|
|
2024
Q1 | $736 | Hold |
40
| – | – | ﹤0.01% | 3172 |
|
|
2023
Q4 | $636 | Hold |
40
| – | – | ﹤0.01% | 3073 |
|
|
2023
Q3 | $754 | Hold |
40
| – | – | ﹤0.01% | 2929 |
|
|
2023
Q2 | $904 | Hold |
40
| – | – | ﹤0.01% | 2757 |
|
|
2023
Q1 | $1.02K | Hold |
40
| – | – | ﹤0.01% | 2665 |
|
|
2022
Q4 | $605 | Hold |
40
| – | – | ﹤0.01% | 2587 |
|
|
2022
Q3 | $1K | Hold |
40
| – | – | ﹤0.01% | 2332 |
|
|
2022
Q2 | $0 | Hold |
40
| – | – | ﹤0.01% | 2433 |
|
|
2022
Q1 | $1K | Hold |
40
| – | – | ﹤0.01% | 1893 |
|
|
2021
Q4 | $1K | Buy |
+40
| New | +$1.25K | ﹤0.01% | 1794 |
|
Allworth Financial's CDTX Position: Q1 2026 in Review
Allworth Financial sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 63 shares — an estimated $13.9K sold.
Allworth Financial first reported a position in CDTX in Q4 2021 and held it in 17 quarters. The position peaked at $13.9K in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Allworth Financial reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Allworth Financial sold 63 Cidara Therapeutics shares in Q1 2026, an estimated $13.9K.
- Allworth Financial first reported a position in Cidara Therapeutics in Q4 2021 and held it in 17 quarters.
- Allworth Financial's Cidara Therapeutics position peaked at $13.9K in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.